Gagic Zarko, Ivkovic Branka, Srdic-Rajic Tatjana, Vucicevic Jelica, Nikolic Katarina, Agbaba Danica
University of Banja Luka, Faculty of Medicine, Department of Pharmacy, Save Mrkalja 14, 78000 Banja Luka, Bosnia and Herzegovina.
University of Belgrade, Faculty of Pharmacy, Institute of Pharmaceutical Chemistry, Vojvode Stepe 450, 11000 Belgrade, Serbia.
Eur J Pharm Sci. 2016 Jun 10;88:59-69. doi: 10.1016/j.ejps.2016.04.008. Epub 2016 Apr 8.
Tocopherols and tocotrienols belong to the family of vitamin E (VE) with the well-known antioxidant properties. For certain α-tocopherol and γ-tocotrienol derivatives used as the lead compounds in this study, antitumor activities against various cancer cell types have been reported. In the course of the last decade, structural analogs of VE (esters, ethers and amides) with an enhanced antiproliferative and proapoptotic activity against various cancer cells were synthesized. Within the framework of this study, seven amino acid esters of α-tocopherol (4a-d) and γ-tocotrienol (6a-c) were prepared using the EDC/DMAP reaction conditions and their ability to inhibit proliferation of the MCF-7 and MDA-MB-231 breast cancer cells and the A549 lung cancer cells was evaluated. Compound 6a showed an activity against all three cell lines (IC50: 20.6μM, 28.6μM and 19μM for the MCF-7, MDA-MB-231 and A549 cells, respectively), while compound 4a inhibited proliferation of the MCF-7 (IC50=8.6μM) and A549 cells (IC50=8.6μM). Ester 4d exerted strong antiproliferative activity against the estrogen-unresponsive, multi-drug resistant MDA-MB-231 breast cancer cell line, with IC50 value of 9.2μM. Compared with the strong activity of compounds 4a, 4d and 6a, commercial α-tocopheryl succinate and γ-tocotrienol showed only a limited activity against all three cell lines, with IC50 values >50μM. Investigation of the cell cycle phase distribution and the cell death induction confirmed an apoptosis of the MDA-MB-231 cells treated with 4d, as well as a synergistic effect of 4d with the known anticancer drug doxorubicin. This result suggests a possibility of a combined therapy of breast cancer in order to improve the therapeutic response and to lower the toxicity associated with a high dose of doxorubicin. The stability study of 4d in human plasma showed that ca. 83% initial concentration of this compound remains in plasma in the course of six hours incubation. The ligand based virtual screening of the ChEMBL database identified new compounds with a potential antiproliferative activity on MCF-7 and on multi-drug resistant MDA-MB 231 breast cancer cells.
生育酚和生育三烯酚属于具有众所周知抗氧化特性的维生素E(VE)家族。对于本研究中用作先导化合物的某些α-生育酚和γ-生育三烯酚衍生物,已报道了其对各种癌细胞类型的抗肿瘤活性。在过去十年中,合成了对各种癌细胞具有增强的抗增殖和促凋亡活性的VE结构类似物(酯、醚和酰胺)。在本研究框架内,使用EDC/DMAP反应条件制备了α-生育酚(4a-d)和γ-生育三烯酚(6a-c)的七种氨基酸酯,并评估了它们抑制MCF-7和MDA-MB-231乳腺癌细胞以及A549肺癌细胞增殖的能力。化合物6a对所有三种细胞系均表现出活性(MCF-7、MDA-MB-231和A549细胞的IC50分别为20.6μM、28.6μM和19μM),而化合物4a抑制MCF-7(IC50 = 8.6μM)和A549细胞(IC50 = 8.6μM)的增殖。酯4d对雌激素无反应、多药耐药的MDA-MB-231乳腺癌细胞系具有很强 的抗增殖活性,IC50值为9.2μM。与化合物4a、4d和6a的强活性相比,市售的α-生育酚琥珀酸酯和γ-生育三烯酚对所有三种细胞系仅表现出有限的活性,IC50值>50μM。对细胞周期阶段分布和细胞死亡诱导的研究证实,用4d处理的MDA-MB-231细胞发生了凋亡,以及4d与已知抗癌药物阿霉素的协同作用。该结果提示了联合治疗乳腺癌以改善治疗反应并降低与高剂量阿霉素相关毒性的可能性。4d在人血浆中的稳定性研究表明,在六小时孵育过程中,该化合物约83%的初始浓度仍保留在血浆中。基于配体的ChEMBL数据库虚拟筛选鉴定出了对MCF-7和多药耐药的MDA-MB 231乳腺癌细胞具有潜在抗增殖活性的新化合物。